2003 journal article

A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: effects on dermal cellularity and cutaneous tumour necrosis factor-alpha

VETERINARY DERMATOLOGY, 14(1), 37–46.

By: T. Olivry n, S. Dunston n, C. Rivierre n, H. Jackson n, K. Murphy n, E. Peters n, G. Dean n

Contributors: T. Olivry n, S. Dunston n, C. Rivierre n, H. Jackson n, K. Murphy n, E. Peters n, G. Dean n

author keywords: allergy; atopic dermatitis; atopy; canine; misoprostol; randomized controlled trial; tumour necrosis factor alpha
MeSH headings : Administration, Oral; Animals; Dermatitis, Atopic / drug therapy; Dermatitis, Atopic / veterinary; Dermatologic Agents / administration & dosage; Dermatologic Agents / pharmacology; Dermatologic Agents / therapeutic use; Dog Diseases / drug therapy; Dog Diseases / pathology; Dogs; Double-Blind Method; Female; Fluorescent Antibody Technique, Indirect / veterinary; Male; Misoprostol / administration & dosage; Misoprostol / pharmacology; Misoprostol / therapeutic use; RNA, Messenger / drug effects; RNA, Messenger / metabolism; Treatment Outcome; Tumor Necrosis Factor-alpha / drug effects; Tumor Necrosis Factor-alpha / metabolism
TL;DR: The modest efficacy of misoprostol for treatment of canine AD is confirmed and its mild anti-allergic effects are suggested to be associated with either inhibition of inflammatory cell emigration or TNFalpha production. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (Web of Science; OpenAlex)
Sources: Web Of Science, ORCID
Added: August 6, 2018

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.